Chloroxyquinoline en es it fr

Chloroxyquinoline Brand names, Chloroxyquinoline Analogs

Chloroxyquinoline Brand Names Mixture

  • No information avaliable

Chloroxyquinoline Chemical_Formula


Chloroxyquinoline RX_link

Chloroxyquinoline fda sheet

Chloroxyquinoline msds (material safety sheet)

Chloroxyquinoline MSDS

Chloroxyquinoline Synthesis Reference

No information avaliable

Chloroxyquinoline Molecular Weight

1749.82 g/mol

Chloroxyquinoline Melting Point

No information avaliable

Chloroxyquinoline H2O Solubility


Chloroxyquinoline State


Chloroxyquinoline LogP

No information avaliable

Chloroxyquinoline Dosage Forms

Vials containing colistimethate sodium or pentasodium colistinmethanesulfonate (150 mg colistin base activity) for injection.

Chloroxyquinoline Indication

For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.

Chloroxyquinoline Pharmacology

Colistimethate is a polymyxin antibiotic agent. Originally, colistimethate sodium was thought to be less toxic than polymyxin B; however, if the drugs are administered at comparable doses, their toxicities may be similar. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins.

Chloroxyquinoline Absorption

Very poor absorption from gastrointestinal tract.

Chloroxyquinoline side effects and Toxicity

Oral LD50 in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.

Chloroxyquinoline Patient Information

Chloroxyquinoline Organisms Affected

Gram-negative bacilli